Occurrence of S100A7 in a large sample-set of breast cancer tissues

2010

Proteomic approach to characterize homozygous Citrus clementina Hort. ex Tan. Genotypes

2011

Clinicopathological correlations of MMP-2 and MMP-9 in breast cancer

2009

Differential proteomics of thyroid carcinoma cell lines

2011

Levels of circulating gelatinases and proteomic correlations in breast cancer patients.

2008

Anti-oncogenic role of decorin: identification of new markers.

2009

Fibroblast’s role in breast cancer: a proteomic approach

2008

Fibroblasts are the major mesenchymal cell types committed to the matrix formation and renewal. Moreover they are the main source of paracrine factors that influence the growth of epithelial cells of neighbouring tissues. For these properties they may be involved in tumourigenesis, either by remodelling the tumor-associated extracellular matrix (ECM), and by the production of paracrine factors that influence the growth of carcinoma cells. Studies on fibroblasts associated to carcinomas have documented their phenotypic modifications, including abnormal migratory behaviour in vitro and growth factors altered expression(Schor & Schor, 2001). In addition, fibroblasts often recruit inflammat…

Proteomic Detection of Breast-Cancer Subpopulations.

2007

Prognostic and functional significant of mmp2 and mmp9 in breast cancer unveiled by proteomic analysis

2022

The fibroblasts: co-actors in cancer.

2008

Proteomic analysis of Herceptin-resistance breast cancer cells

2009

Differential proteomic and phenotypic behavior of papillary and anaplastic thyroid carcinoma cell lines: an updated study

2012

Breast cancer proteomics: from research to clinical applications.

2008

The exponentially increasing volume of information extracted from genomic and proteomic applications on cancer, while providing new insights into molecular composition of cancer cells and tissues, imposes new challenges on data rationalization as a tool for clinically relevant biomarker discovery. Breast cancer represents the most frequent and potentially aggressive type of cancer and, moreover, it is one of the most enigmatic and poorly predictable in its evolution, likely because it includes several different forms that behave differently among patients. Current clinical parameters for breast cancer diagnosis and cure are: tumour size, axillary lymph node status, histological grading and …

S100S PROTEIN EXPRESSION IN A LARGE SAMPLE-SET OF BREAST CANCER TISSUES

2010

S100 proteins are low molecular weight proteins ranging in size from 9 to 13 kDa. They form homo- and heterodimers and even oligomers and are expressed in tissue and cell-specific manner [1]. It is well documented, infact, that S100 proteins have a broad range of intracellular and extracellular functions. Intracellular functions include regulation of protein phosphorylation, enzyme activity, calcium homeostasis, regulation of cytoskeletal components and regulation of transcriptional factors, so they are involved in several biological processes including cell cycle regulation, cell growth, cell differentiation, and motility [2]. Extracellularly they act in a cytokine like manner through the …

Zymographic detection of MMP-2 and MMP-9 in breast cancer sera patients during chemotherapy.

2007

MMP-2, MMP-9 and MMP-14 in breast cancer: clinicopathological correlations.

2009

Evaluation of cellular response of breast cancer cells grown on distinctive collagen substrates

2008

LARGE-SCALE COMPARATIVE PROTEOMICS OF BREAST CANCER SURGICAL TISSUES

2009

Comparative proteomics of breast cancer surgical tissues

2009

Proteomic Detection of Breast-Cancer Subpopulation

2007

Correlation between MMPS and proteomic profiles of breast cancer tissues

2009

Gene ontology-based annotation and comparative analysis of proteins extracted from proteomics of 100 breast cancer patients.

2009

Background: Current clinical parameters for breast cancer diagnosis and therapy are: tumour size, axillary lymph node status, histological grading and presence or absence of metastases. Prognostic/predictive properties, such as oestrogen and progesterone receptor status, and human epidermal growth factor receptor (HER-2/neu) status are currently used for therapeutic decision. Conversely, it is now emerging that the number of genetic mutations and epigenetic deregulations in cancer is far more higher than previously thought. Therefore, proteomic screening for differential protein expression in subsets of tumor samples is an essential tool for generating data bases and biomarker discovery. Th…

PROTEOMIC SIGNATURE OF BREAST CANCER TISSUES FOR PATIENTS STRATIFICATION

2012

Analisi comparativa tra linee cellulari di carcinoma tiroideo papillare ed anaplastico

2013

Large-scale proteomic identification of S100 proteins in breast cancer tissues

2010

Abstract Background Attempts to reduce morbidity and mortality in breast cancer is based on efforts to identify novel biomarkers to support prognosis and therapeutic choices. The present study has focussed on S100 proteins as a potentially promising group of markers in cancer development and progression. One reason of interest in this family of proteins is because the majority of the S100 genes are clustered on a region of human chromosome 1q21 that is prone to genomic rearrangements. Moreover, there is increasing evidence that S100 proteins are often up-regulated in many cancers, including breast, and this is frequently associated with tumour progression. Methods Samples of breast cancer t…

Cross-talk between breast cancer cells and fibroblasts in coculture system.

2005

CIRCULATING AND TISSUE FORMS OF MMP2 AND MMP9 IN BREAST CANCER PROGRESSION

2010

Tumor progression and metastasis represent the leading causes of cancer related death. One of the major features that may contribute to neoplastic cell dissemination is the progressive and local degradation of the extracellular matrix (ECM) surrounding the primary tumour. Degradation of the ECM requires the coordinated action of a number of enzymes produced locally by neoplastic cells and/or stromal cells. Five categories of proteinases have been implicated in the invasive process: serine, cysteine, aspartic, threonine proteinases and matrix metalloproteinases (MMPs), also known as matrixins, which play a key role as terminal effectors of the proteolytic cascade. At present 23 members of th…

Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines.

2013

Abstract Thyroid carcinomas account for a minority of all malignant tumours but, after those of the gonads, they represent the most common forms of endocrine cancers. They include several types, among which the papillary thyroid cancer (PTC) and the anaplastic thyroid cancer (ATC) are the best known. The two hystotypes display significant biological and clinical differences: PTC is a well differentiated form of tumour with a high incidence and a good prognosis, while the ATC is less frequent but represents one of the most aggressive endocrine tumours with morphological features of an undifferentiated type. To date, as far as we know, no conclusive studies, useful to design arrays of molecul…

New protein clustering of breast cancer tissue proteomics using actin content as a cellularity indicator

2008

In the present study, we report the comparative proteome profiles of proteins solubilized from 37 breast cancer surgical tissues, normalized for the actin content. Blood-derived proteins were excluded from the analysis. Among the tumor-derived protein spots, a large proportion (39%) was found present in all patients. These included several glycolytic enzymes, detox and heat shock proteins, members of annexin and S100 protein families, cathepsin D, and two “rare” proteins, DDAH2 involved in the angiogenesis control, and the oncogene PARK7. Other proteins, such as psoriasin, galectin1, cofilin, peroredoxins, SH3L1, and others, showed sporadic presence and high expression level, which suggests…

Comparative detection of matrix metalloproteinase-2 and -9, interleukin-6 and c-reactive protein in breast cancer serum of patients during neoadjuvan…

2007

Fibroblast’s influence on breast cancer cells.

2006

New Insights into the Occurrence of Matrix Metalloproteases -2 and -9 in a Cohort of Breast Cancer Patients and Proteomic Correlations

2018

Matrix metalloproteases (MMPS) are a family of well-known enzymes which operate prevalently in the extracellular domain, where they fulfil the function of remodeling the extracellular matrix. Within the about 26 family members, encoded by 24 genes in humans, MMP-2 and MMP-9, have been regarded as the primary responsibility for the basement membrane and pericellular ECM rearrangement. In cases of infiltrating carcinomas, which arise from the epithelial tissues of a gland or of an internal organ, a marked alteration of the expression and the activity levels of both MMPs is known to occur. Present investigation represents the continuation and upgrading of our previous studies, now focusing on …

Differential occurrence of S100A7 in breast cancer tissues: A proteomic-based investigation

2012

Purpose The present study reports for the first time a large-scale proteomic screening of the occurrence, subcellular localization and relative quantification of the S100A7 protein among a group of 100 patients, clinically grouped for the diagnosis of infiltrating ductal carcinoma (IDC). Experimental design To this purpose, the methods of differential proteomics, Western blotting, and immunohistochemistry were used. Results The identity of two isoforms of the protein was assessed by mass spectrometry and immunologically confirmed. Moreover, we proved by immunocytochemical applications the exclusive localization of the protein within the neoplastic cells. The correlation of S100A7 expression…

Breast cancer cells exhibit selective modulation induced by different collagen substrates.

2008

During the invasive phase of malignant tumors, neoplastic cells break into the basal lamina and enter in contact with the underlying connective tissue, which concurrently undergoes extensive modifications. The aim of our present minireview is to focus the changes in the collagenous matrix occurring during breast cancer progression and to explore the possible effects of different collagen substrates on breast cancer cell behavior and proteomic modulation.

DIFFERENTIAL PROTEOMIC ANALYSIS OF THYROID CARCINOMA CELL LlNES

2011

Herceptin-resistance in breast cancer cells: a proteomic study.

2009

HER-2 is a cell membrane protein that belongs to the ErbB family of receptor tyrosine kinases (HER-1, HER-2, HER-3, HER-4). The over-expression of HER-2, which results in the 25-30% of breast cancer patients, is considered a predictive and prognostic marker for breast cancer malignancy and invasiveness and makes HER-2 an excellent therapeutic target. In the last years new therapeutic strategies have been improved in order to better deal tumor diseases an to minimize collateral effects due to classic chemotherapy in patients. In this way, a new approach was the somministration of humanized antibodies directed against tumor-associated molecular targets. Among these ones Herceptin, an anti-neo…

Proteomic detection of S100 proteins in breastcancer tissues

2010

Urinary Proteomic Profile Of A Multiple Myeloma Affected Patient

2012

New insight on genomic and proteomic profiling of decorin-transfected breast cancer cells.

2007

LARGE-SCALE SCREENING OF MATRIX METALLOPROTEINASES IN BREAST CANCER PATIENTS AND CLINICAL-MOLECULAR CORRELATIONS

2009

Cytoskeleton and Proteomic Changes Induced by Fibroblasts on Breast Cancer Cells

2007

Herceptin-resistance in breast cancer cells: a proteomic approach

2009

Large-scale comparative proteomics of breast surgical tissues

2009

IDENTIFICATION OF TYPE V COLLAGEN-BINDING PROTEINS IN 8701-BC BREAST CANCER CELLS

2012

Proteomica comparata di un frammento chirurgico di carcinoma del colon e della metastasi epatica associata

2013

Circulating levels of Matrix Metalloproteinases (MMP-2 and MMP-9), CRP and IL-6 during therapeutic treatment of patients with breast cancer

2008

Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts.

2006

According to recent statistics, breast cancer remains one of the leading causes of death among women in Western countries. Breast cancer is a complex and heterogeneous disease, presently classified into several subtypes according to their cellular origin. Among breast cancer histotypes, infiltrating ductal carcinoma represents the most common and potentially aggressive form. Despite the current progress achieved in early cancer detection and treatment, including the new generation of molecular therapies, there is still need for identification of multiparametric biomarkers capable of discriminating between cancer subtypes and predicting cancer progression for personalized therapies. One esta…

S-100 calcium binding proteins as potential markers for breast cancer metastasis.

2009

The S-100 family of calcium-binding proteins includes about 20 members of low molecular weight characterized by two consecutive EF hands domains. They make interactions with cellular target proteins in a calcium-dependent manner; therefore they are thought to regulate a variety of physiological functions, such as cell proliferation, signal transduction, cell adhesion, motility as well as cancer metastasis.

Permissive and restrictive influences from breast cancer stroma

2010

The turn-over of extracellular matrix is a physiological process, that in normal conditions and in wound healing respond to spatial and temporal regulatory mechanisms, involving several cell-matrix interaction pathways. Profound changes occur both at cellular and extracellular level, during the progression of various forms of invasive carcinomas. Collagen alterations and cellular effects. The ultrastructural and biochemical analyses of the collagenous stroma of invasive ductal breast carcinoma have demonstrated the occurrence of extensive fragmentation of pre-existing collagen fibrils and new deposition of thinner fibrils formed mostly by 1(I)3 homotrimer collagen of type I [1-3], which app…

PROTEOMIC MODULATION IN BREAST CANCER CELLS INDUCED BY MICROENVIRONMENT COMPONENTS

2007

Different collagen substrates induce the expression of alternative forms of keratins and vimentin in breast cancer cells.

2005

AUTOANTIBODIES IDENTIFICATION IN BREAST CANCER SERA BY PROTEOMIC APPROACH

2011

EFFETTI DEL TRASTUZUMAB SUL PROTEOMA DI CELLULE DI CARCINOMA MAMMARIO OVER-ESPRIMENTI HER-2

2013

Matrix metalloproteases monitoring during neoadjuvant breast cancer therapy. An ongoing study.

2007

Fibroblasts enhance proliferation and invasion of Breast Cancer Cells (8701-BC)

2009

Identificazione di forme multiple di cheratine 8, 18 e vimentina espresse da cellule di carcinoma mammario coltivate su differenti substrati collagene

2004

A combined determination of circulating gelatinases and inflammatory markers in breast cancer patients during therapeutic treatment

2008

Proteomic discovery of new differentiation markers in the U937 cell line

2009

Identification of multiple forms of keratins expressed by brest cancer cells coltured on different collagen substrates.

2004

The challenge of tumor microenvironment

2008

Multiple changes induced by fibroblasts on breast cancer cells.

2010

It is now widely recognised that the cross-talk between cancer and stromal cells may play a crucial role in cancer progression. However little is known about the complex underlying molecular mechanisms that occur within the tumor microenvironment. Fibroblasts are the major stromal cells with multiple roles, especially towards both the extracellular matrix and the neighbouring cell population, including neoplastic cells. Consequently, proteomic analyses would provide a wider resource for a better understanding of the potential modulating effects exerted by fibroblasts on cancer cells. In this report we describe the effects of fibroblast stimulation on the breast cancer cell line (8701-BC) pr…